Thompson Named to Generation Bio Scientific Advisory Board
5 October 2018 - - US-based genetic medicines developer Generation Bio has appointed Richard Thompson, BM BCh, DM, a world-renowned specialist in pediatric liver disease, to its scientific advisory board, the company said.

Thompson is the Professor of Molecular Hepatology at King's College London and honorary consultant pediatric hepatologist at King's College Hospital, London.

He specialises in pediatric liver disease and is particularly interested in genetic liver disease in both children and adults.

Through worldwide collaborations, Thompson's lab continues to identify new causes of genetic liver disease.

Thompson served as the clinical lead for genomics and the 100,000 genome project at King's College Hospital, and is the clinical lead for a diagnostic laboratory specialising in liver and gastrointestinal disease.

Generation Bio is a biotechnology company developing a breakthrough class of genetic medicines to enable a new generation of people to live unaffected by inherited disease.

The company's therapies are based on its proprietary ceDNA technology, which delivers durable, high levels of gene expression and can be re-dosed to titrate to effect and to sustain impact over a lifetime.

Generation Bio was founded and launched by Atlas Venture and is headquartered in Cambridge, Mass.